UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 736
- Registration Number
- NCT01255761
- Locations
- 🇺🇸
241, Jonesboro, Arkansas, United States
🇺🇸103, Fullerton, California, United States
🇺🇸203, Loma Linda, California, United States
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 221
- Registration Number
- NCT01242488
- Locations
- 🇺🇸
132, Houston, Texas, United States
🇺🇸181, Houston, Texas, United States
🇺🇸158, San Diego, California, United States
Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 192
- Registration Number
- NCT01236001
Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 100
- Registration Number
- NCT01235403
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 41
- Registration Number
- NCT01235598
- Locations
- 🇵🇱
018, Warszawa, Poland
🇩🇰003, Frederiksberg, Denmark
🇩🇰002, Hellerup, Denmark
Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution
Completed
- Conditions
- First Posted Date
- 2010-09-28
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 101
- Registration Number
- NCT01210690
- Locations
- 🇵🇱
065, Gdansk, Poland
🇮🇹032, Milano, Italy
🇩🇪027, Berlin, Germany
Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 16
- Registration Number
- NCT01190410
- Locations
- 🇺🇸
126, Morristown, New Jersey, United States
🇺🇸104, Baltimore, Maryland, United States
🇺🇸114, Orange, California, United States
Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise
- First Posted Date
- 2010-04-30
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 687
- Registration Number
- NCT01113710
Named Patient Program With Rotigotine Transdermal System
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 520
- Registration Number
- NCT01095484
- Locations
- 🇺🇸
036, Berkeley, California, United States
🇺🇸046, Houston, Texas, United States
🇺🇸085, Fairhope, Alabama, United States
National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)
Completed
- Conditions
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 12500
- Registration Number
- NCT01095393
© Copyright 2024. All Rights Reserved by MedPath